Neisserial vaccine compositions comprising a combination of antigens

Abstract

The present invention relates to immunogenic compositions and vaccines for the treatment and prevention of Neisserial disease. Immunogenic compositions of the invention contain combinations of antigens selected from at least two different classes of antigens including adhesins, autotransporter proteins, toxins, iron acquisitions proteins and membrane-associated protein (preferably integral outer membrane protein)s. Such combinations of antigens are able to target the immune response against different aspects of the neisserial life cycle, resulting in a more effective immune response.

1 . A vaccine composition comprising immunogenic levels of at least one Neisserial autotransporter protein antigen, at least one Neisserial Fe acquisition protein antigen, and at least one different Neisserial outer membrane protein antigen, wherein the at least one Neisserial autotransporter protein antigen is NadA, and the at least one Neisserial Fe acquisition protein antigen is transferrin binding protein related protein (Tbprp), said composition further comprising an outer membrane vesicle preparation comprising an LPS immunotype L3. 
     
     
         2 . The vaccine composition of  claim 1 , wherein at least one of the Neisserial protein antigens is an antigen derived from  Neisseria meningitidis.    
     
     
         3 . The vaccine composition of  claim 1 , wherein all Neisserial protein antigens are derived from  N. meningitidis.    
     
     
         4 . The vaccine composition of  claim 1  further comprising one or more bacterial capsular polysaccharides or oligosaccharides. 
     
     
         5 . The vaccine composition of  claim 4 , wherein the capsular polysaccharides or oligosaccharides are derived from bacteria selected from the group consisting of:  Neisseria meningitidis  serogroup A, C, Y and W-135. 
     
     
         6 . The vaccine composition of  claim 1  further comprising an adjuvant. 
     
     
         7 . The vaccine composition of  claim 6 , wherein the adjuvant comprises an aluminum salt. 
     
     
         8 . The vaccine composition of  claim 6 , wherein the adjuvant comprises aluminum hydroxide gel. 
     
     
         9 . The vaccine composition of  claim 1 , wherein the outer membrane protein antigen is GNA1870.